Investor Relations

Latest News

May 8, 2025

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

View Press Release

Apr 1, 2025

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

View All News

BiomX Company Introduction

View Presentation

First Quarter 2025 Financial Results Conference Call

View Event Add to Calendar View All

Company Overview

BiomX is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot infections and osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

View Management Team View Board of Directors

FY 2024

Fiscal Year Ended Dec 31, 2024

Earnings Release

PDF HTML

10-K

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Investor Contact Information

Company

BiomX, Inc.
708 Quince Orchard Rd
Suite 205
Gaithersburg, MD 20878
USA
info@biomx.com